Publicaciones (177) Publicaciones de EVA MARÍA CIRUELOS GIL

2024

  1. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy

    npj Breast Cancer, Vol. 10, Núm. 1

  2. Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2647-2664), 10.1007/s12094-023-03215-4)

    Clinical and Translational Oncology

  3. Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer

    JNCI Cancer Spectrum, Vol. 8, Núm. 1

  4. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

  5. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

    ESMO Open, Vol. 9, Núm. 3

  6. Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management

    Clinical and Translational Oncology

2023

  1. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1370-1375

  2. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1376-1382

  3. Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer

    Breast, Vol. 71, pp. 42-46

  4. Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

    Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4166-4177

  5. CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 8, pp. 1557-1568

  6. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer

    Nature Communications, Vol. 14, Núm. 1

  7. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

    Annals of Oncology, Vol. 34, Núm. 4, pp. 397-409

  8. HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer

    Frontiers in Oncology, Vol. 13

  9. Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence

    Geburtshilfe und Frauenheilkunde, Vol. 84, Núm. 2, pp. 164-184

  10. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10411, pp. 1423-1433

  11. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

    Annals of Oncology, Vol. 34, Núm. 8, pp. 670-680

  12. Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis

    ESMO Open, Vol. 8, Núm. 3

  13. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2647-2664

  14. Spatial predictors of immunotherapy response in triple-negative breast cancer

    Nature, Vol. 621, Núm. 7980, pp. 868-876